Gilead Sciences, Inc. (GILD) TD Cowen 45th Annual Healthcare Conference (Transcript)

Group 1 - Gilead Sciences, Inc. is experiencing strong performance in a challenging biotech market, with its stock significantly outperforming peers [1] - The company reported an 8% year-on-year growth in 2024, driven by demand-led volume growth in key products such as BIKTARVY, DESCOVY, and its oncology and liver portfolios [4] - For 2025, Gilead's guidance indicates a flat year-over-year product sales growth of approximately -0.5%, excluding BIKTARVY, with expectations for continued growth in the coming years [4]